Does Carbon Black Disaggregate in Lung Fluid? A Critical Assessment

Abstract

Carbon black is an industrially produced particulate form of nearly pure elemental carbon. The basic building blocks of carbon black are (1) primary particles, minute pieces of matter with defined physical boundaries; (2) aggregates, collections of strongly bound or fused particles; and (3) agglomerates, collections of weakly bound aggregates. Industrial carbon black is produced within a closed reactor where the primary particles form aggregates, which become the indivisible entities of carbon black. These aggregates then form agglomerates, which are the typical form of carbon black in commerce. Carbon black is often used in in vitro and in vivo particle toxicology investigations as a reference nanoparticle. The toxicology studies often report the sizes of the primary particles but rarely the sizes of the aggregates or agglomerates. It appears in many cases that there is a limited understanding of the fact that carbon black typically does not exist as primary particles but instead exists as aggregates and agglomerates. Moreover, many toxicology studies manipulate carbon black particles in order to disperse them so that the form of carbon black used in these toxicology studies may be substantially different from the form that may be encountered in the workplace environment. Since the main exposure route for carbon black is inhalation, the question arose as to whether inhaled carbon black may deagglomerate or disaggregate to either smaller aggregates or primary particles when in contact with lung fluids. This question relates to the concern that there may be additional hazards of smaller particles, such as their ability to translocate to tissues and organs beyond the lung and the ability to pass through the blood-brain barrier. The purpose of this assessment is to review the existing literature for evidence as to whether carbon black deagglomerates or disaggregates into smaller aggregates or primary particles when in contact with lung fluid. On the basis of a review of the physical characteristics of commercial carbon black and various toxicology studies, it appears that commercially produced carbon black in contact with lung fluid is unlikely to deagglomerate or disaggregate into smaller aggregates or primary particles.

Biokinetics of nanomaterials: The role of biopersistence

“…A contentious issue is the potential deagglomeration of NMs. One side argues that currently there is no evidence and that it is unlikely with respect to the underlying knowledge of physical behavior that NMs deagglomerate in biological milieus (Creutzenberg et al 2012a; Levy et al 2012; Preining 1998). The other side counters that deagglomeration in the lung may occur for some, but not necessarily for all NMs (Mercer et al 2013; Oberdörster et al 1992a), keeping in mind the many possible, yet untested, NMs.…”

Carbon black nanoparticles induce biphasic gene expression changes associated with inflammatory responses in the lungs of C57BL/6 mice following a single intratracheal instillation

“…Carbon black particles with diameters less than 100 nm are referred to as ultrafine powder or carbon black nanoparticles (CBNPs) and are used as reference material for diesel exhaust particles stripped of their adsorbed compounds in toxicological studies (Levy et al, 2012;Kyjovska et al, 2015b). CBNPs are one of the most widely produced and used nanomaterial.…”

Size-Dependent Cytotoxicity of Nanocarbon Blacks

“…It is reported that annual carbon black (CB) emissions in China were 1957 Gg in 2007 and increasing in recent years [3]. NCBs are massively manufactured and widely used in industry, for purposes such as colorant of inks, coatings and plastic goods, UV shielding agent of plastic goods and as a reinforcing agent and filler of rubber accounting for 94% of the total carbon black production [4]. In recent years, researchers have carried out a series of in vivo and in vitro biocompatibility investigations of NCBs.…”